TrialHuman vaccines & immunotherapeutics2018

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.

Remon Abu-Elyazeed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.